Commercial Kit for screening for hereditary tyrosinemia type 1 (HT1)
NHS England · awarded 31 March 2025 · delivered in England
£1.7m
Award value
£1,677,290
1
Supplier
Recorded as a small or medium-sized business
31 Mar 2027
Runs until
from 1 Apr 2025
Who
| Buyer | NHS England Leeds |
|---|---|
| Supplier |
Revvity (UK) Limited |
| Category | services |
| Classification | Blood-testing reagents CPV 33696200 |
| Notice published | 27 August 2025 |
What it is for
Newborn Blood Spot screening (NBS) is a national programme offered to all babies born in the UK, and it currently screens for 9 rare but potentially lethal conditions. The blood spot screening sample is taken from the baby's heel collected on a filter paper dried blood spot (DBS) card. The blood sample is analysed by one of 13 newborn screening laboratories in England
Read the original award notice on Contracts Finder →
Other contracts from this buyer
1269 awards on file, worth £50.2bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 4 Mar 2026 | New Hospital Programme - Hospital 2.0 Alliance (H2A) FrameworkEngland | NHS England | Willmott Dixon Construction Limited +9 | £37.0bn |
| 24 Mar 2025 | NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands | NHS England | CSL Behring UK Ltd +71 | £1.2bn |
| 1 Jul 2025 | NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | Biogen +20 | £986.3m |
| 19 Dec 2024 | NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinScotland | NHS England | CSL Behring UK Ltd +5 | £905.2m |
| 31 May 2024 | NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands | NHS England | Pfizer Ltd +8 | £765.0m |
Everything NHS England has awarded →
Other contracts won by this supplier
11 awards on file, worth £9.4m.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 25 Mar 2026 | Provision of Assay Kits for SCID & SMA In-Service Evaluations - EONIS-Q Revvity | NHS England | Revvity (UK) Limited | £4.1m |
| 31 Mar 2025 | Commercial Kit for screening for hereditary tyrosinemia type 1 (HT1)England | NHS England | Revvity (UK) Limited | £1.7m |
| 22 Apr 2026 | Provision of Assay Kits for SCID Evaluation: EONIS-QEngland | NHS England | Revvity (UK) Limited | £950k |
| 15 Aug 2024 | Revvity ConsumablesEngland | UKHSA | Revvity (UK) Ltd. | £750k |
| 15 Aug 2024 | Revvity ConsumablesEngland | UKHSA | Revvity (UK) Ltd. | £750k |